Microcap Ledger SAB Biotherapeutics, Inc. $SABS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Miami Beach, FL
- Fiscal year end
- December 31
- Shares outstanding
- 90,986,368 [10-Q 2026-08-06]
What the company doesAI summary of filing
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. The company's lead product candidate, SAB-142, is a human anti-thymocyte globulin in clinical development for type 1 diabetes, with a Phase 2b registrational trial (SAFEGUARD) initiated in 2025 and first patient dosed in December 2025. SAB Biotherapeutics produces its therapeutic candidates using a proprietary platform based on transchromosomic cattle (Tc-Bovine) engineered to generate disease-targeted human antibodies without human donors or plasma. The company is pre-revenue and generates no current revenue from approved products. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$41.36M | −$24.11M | $8.27M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $0.00 | $13.27M | −$44.78M | $10.50M | [10-K 2026-03-09] |
| FY ended Dec 2024 | $1.32M | −$34.11M | −$34.29M | $8.90M | [10-K 2026-03-09] |
- Quarterly cash burn
- −$12.06M
- Cash runway Estimate
- ~2.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 9,229,274 | [10-Q 2024-11-06] |
| 2025-03-21 | 9,288,868 | [10-K 2025-03-31] |
| 2025-05-02 | 9,291,697 | [10-Q 2025-05-09] |
| 2025-08-01 | 10,411,061 | [10-Q 2025-08-07] |
| 2025-11-10 | 47,606,851 | [10-Q 2025-11-14] |
| 2026-03-02 | 50,951,037 | [10-K 2026-03-09] |
| 2026-05-06 | 76,464,094 | [10-Q 2026-05-12] |
| 2026-08-03 | 90,986,368 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-12-29; declared effective 2026-01-07 [S-3 2025-12-29]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-17 | Kropotova Alexandra | other | 473 | — | [4 2026-09-18] |
| 2026-06-25 | Kropotova Alexandra | other | 988 | — | [4 2026-06-26] |
| 2026-03-24 | Kropotova Alexandra | other | 988 | — | [4 2026-03-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-21 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-07 | 8-K | Regulation FD disclosure |
| 2026-06-18 | 8-K | Shareholder vote results |
Alerts for $SABS
Email me when SAB Biotherapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.